

Applicants: Kenneth A. Jones, et al.
U.S. Serial No. 09/211,755
Filed: December 15, 1998
Page 2

Page 20, line 6, after "W", please insert --(SEQ ID NO: 52)--.

Page 20, line 8, after "V", please insert --(SEQ ID NO: 53)--.

Page 20, line 10, after " T L R T N", please insert --(SEQ ID NO: 54)--.

Page 22, line 12, after "GAGA₃R1", please insert --(SEQ ID NO: 55)--.

Page 28, line 18, after "(ATCC Accession No.", please insert --
203515 --.

Page 28, line 21, after "(ATCC Accession No.", please insert --
203515 --.

Page 33, line 16, after "(ATCC Accession No.", please insert --
203515 --.

Page 33, line 19, after "(ATCC Accession No.", please insert --
203515 --.

Page 33, line 25, please delete "December 9, 1998" and insert --
December 10, 1998--.

Page 33, line 30, after "No.", please insert -- 203515 --.

Page 47, line 13, after "(ATCC Accession No.", please insert --
203515 --.

Page 49, line 26, after "(ATCC Accession No.", please insert --
203515 --.c

Page 56, line 12, after "(ATCC Accession No.", please insert --

Applicants: Kenneth A. Jones, et al.
U.S. Serial No. 09/211,755
Filed: December 15, 1998
Page 3

203515 --.

Page 61, line 8, after "(ATCC Accession No.", please insert --
203515 --.

Page 63, line 9, after "IKN", please insert --(SEQ ID NO: 48)--.

Page 63, line 11, after "EKT", please insert --(SEQ ID NO: 49)--.

Page 63, line 13, after "R", please insert --(SEQ ID NO: 50)--.

Page 63, line 14, after " QKLLVIVGGMLLIDLCILICWQ", please insert
--(SEQ ID NO: 51)--.

Page 63, line 16, after "W", please insert --(SEQ ID NO: 52)--.

Page 63, line 18, after "V", please insert --(SEQ ID NO: 53)--.

Page 63, line 20, after " T L R T N", please insert --(SEQ ID NO:
54)--.

In the Claims:

Please cancel claims 1-17, 50, and 82 without prejudice to
applicants' right to pursue the subject matter of these claims
in a future continuation or divisional application.

Please add new claims 190-249 as follows:

~~190~~ (New) A process for identifying a chemical compound
which specifically binds to a mammalian GABA_BR1/R2
receptor which comprises contacting cells containing
nucleic acid encoding and expressing on their cell
surface the GABA_BR1/R2 receptor or a membrane fraction
from such cells, wherein such cells or membrane